82804-026-90 (Atorvastatin 40mg 1000s Tab 1)
Atorvastatin Calcium Tablet, Film Coated
Product Images NDC 82804-026
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Atorvastatin Calcium (NDC 82804-026). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Atorvastatin-fig-1 (Atorvastatin Fig 1)
The text provided appears to be a table showing the cumulative incidence percentages for two treatments, "Atorastatn" and "Placsbo," over a period of 0 to 35 years. The cumulative incidence percentages range from 10% to 40%. The table also includes additional information related to "HR" (hazard ratio) and "p" values.*
Atorvastatin-fig-2 (Atorvastatin Fig 2)
This text appears to be a statistical analysis of cumulative hazard percentages for a study comparing a placebo to the drug Atorvastatin. The hazard ratio (HR) for Atorvastatin compared to placebo is reported as 0.63 with a confidence interval of 0.48-0.83, and a p-value of 0.001, indicating a statistically significant difference between the two groups. The study tracked the time to the first primary endpoint over a four-year follow-up period.*
Atorvastatin-fig-3 (Atorvastatin Fig 3)
Subjects in the study were divided into two groups receiving different doses of Atorvastatin (10 mg and 80 mg). The percentage of subjects experiencing a particular event was not specified. However, the study found that the higher dose of Atorvastatin (80 mg) had a statistically significant lower risk of experiencing a major cardiovascular endpoint compared to the lower dose (10 mg). The hazard ratio (HR) for the higher dose was 0.78 (95% CI: 0.69-0.89, p=0.0002). The time to the first major cardiovascular endpoint was evaluated over a period of four years.*
Atorvastatin-st (Atorvastatin St)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
